id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-D-0611-0082,FDA,FDA-2011-D-0611,Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the BPCI Act Guidance for Industry,Other,Guidance,2020-11-20T05:00:00Z,2020,11,2020-11-20T05:00:00Z,,2024-11-06T23:43:39Z,,1,0,090000648496c7ea
FDA-2011-D-0611-0081,FDA,FDA-2011-D-0611,Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the Biologics Price Competition and Innovation Act of 2009; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2020-11-20T05:00:00Z,2020,11,2020-11-20T05:00:00Z,2021-01-20T04:59:59Z,2021-01-21T02:00:45Z,2020-25606,0,0,090000648496ac54